| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
SpringWorks Therapeutics Inc (NASDAQ: SWTX)
SWTX Technical Analysis
5
| As on 9th Jun 2023 SWTX STOCK Price closed @ 27.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 39.11 & Strong Sell for SHORT-TERM with Stoploss of 57.67 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SWTXSTOCK Price
| Open | 27.13 | Change | Price | % |
| High | 28.23 | 1 Day | 0.09 | 0.33 |
| Low | 26.91 | 1 Week | -0.13 | -0.47 |
| Close | 27.25 | 1 Month | 4.10 | 17.71 |
| Volume | 560779 | 1 Year | -41.75 | -60.51 |
| 52 Week High 70.99 | 52 Week Low 18.36 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SWTX Daily Charts |
SWTX Intraday Charts |
Whats New @ Bazaartrend |
SWTX Free Analysis |
|
|
SWTX Important Levels Intraday
| RESISTANCE | 29.79 |
| RESISTANCE | 28.98 |
| RESISTANCE | 28.47 |
| RESISTANCE | 27.97 |
| SUPPORT | 26.53 |
| SUPPORT | 26.03 |
| SUPPORT | 25.52 |
| SUPPORT | 24.71 |
SWTX Forecast May 2024
| 4th UP Forecast | 54.5 |
| 3rd UP Forecast | 45.76 |
| 2nd UP Forecast | 40.36 |
| 1st UP Forecast | 34.96 |
| 1st DOWN Forecast | 19.54 |
| 2nd DOWN Forecast | 14.14 |
| 3rd DOWN Forecast | 8.74 |
| 4th DOWN Forecast | 0 |
SWTX Weekly Forecast
| 4th UP Forecast | 50.76 |
| 3rd UP Forecast | 43.22 |
| 2nd UP Forecast | 38.56 |
| 1st UP Forecast | 33.90 |
| 1st DOWN Forecast | 20.60 |
| 2nd DOWN Forecast | 15.94 |
| 3rd DOWN Forecast | 11.28 |
| 4th DOWN Forecast | 3.74 |
SWTX Forecast2024
| 4th UP Forecast | 140.17 |
| 3rd UP Forecast | 103.96 |
| 2nd UP Forecast | 81.57 |
| 1st UP Forecast | 59.19 |
| 1st DOWN Forecast | -4.69 |
| 2nd DOWN Forecast | -27.07 |
| 3rd DOWN Forecast | -49.46 |
| 4th DOWN Forecast | -85.67 |
SpringWorks Therapeutics Inc ( NASDAQ USA Symbol : SWTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SWTX Business Profile
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Address: 100 Washington Boulevard, Stamford, CT, United States, 06902
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service